SUMMARY Short-term vasodilators increase exercise cardiac output without an increase in exercise tolerance when administered to chronic heart failure patients. This study was designed to examine cardiac output, oxygen consumption, and lactate metabolism during exercise in chronic heart failure. Thirteen patients participated in 17 studies during control exercise (C) and during vasodilator exercise after short-term treatment with either hydralazine (H) or prazosin (P). Cardiac output increased during exercise both with hydralazine (C = 5.8 2.3 1/min, H = 6.9 i 2.3 1/min; p < 0.001) and with prazosin (C = 5.9 ± 2.3 1/min, P = 7.6 ± 2.7 1/min; p < 0.005). Oxygen consumption did not change during exercise either with hydralazine (C = 663 249 ml/min, H = 651 ± 200 mI/min; p > 0.10) or with prazosin (C = 696 ± 246 ml/min, P= 734 245 ml/min; p > 0.10). IN PREVIOUS REPORTS on the exercise hemodynamics and exercise capacity of chronic heart failure patients administered short-term oral vasodilators," 2 we noted that hydralazine and prazosin increased cardiac output during exercise, but did not increase exercise tolerance. It seemed paradoxical to us that improvement of a fundamental abnormality of chronic heart failure -low cardiac output -should not result in improvement of exercise tolerance. Data concerning changes in oxygen consumption and muscle metabolism should clarify these disparate effects of short-term vasodilators. In this study we examined changes in the metabolism of oxygen and lactate during exercise and during recovery from exercise as affected by short-term oral vasodilators.
IN PREVIOUS REPORTS on the exercise hemodynamics and exercise capacity of chronic heart failure patients administered short-term oral vasodilators," 2 we noted that hydralazine and prazosin increased cardiac output during exercise, but did not increase exercise tolerance. It seemed paradoxical to us that improvement of a fundamental abnormality of chronic heart failure -low cardiac output -should not result in improvement of exercise tolerance. Data concerning changes in oxygen consumption and muscle metabolism should clarify these disparate effects of short-term vasodilators. In this study we examined changes in the metabolism of oxygen and lactate during exercise and during recovery from exercise as affected by short-term oral vasodilators.
Methods Patients
Thirteen patients who had chronic, stable, severe heart failure of either coronary heart disease (nine patients) or idiopathic cardiomyopathy (four patients) etiology were studied. The mean patient age was 60 years (range 44-80 years). Each patient had clinical and laboratory evidence of chronic heart failure, in-cluding previous hospitalization for heart failure symptoms, current physical disability based on dyspnea and fatigue, enlarged heart and third heart sound on physical examination, cardiomegaly on chest x-ray, and depressed ejection fraction by cardiac catheterization or nuclear scintigraphic wall motion study. Patients were either functional class III or IV (New York Heart Association3), but none had acute pulmonary edema within the previous month. Each was taking digoxin and furosemide, and each was continued on these medications throughout the study.
Variables Measured and Calculated
Intracardiac pressures were measured from a SwanGanz triple-lumen catheter that had been inserted into the pulmonary artery. Cardiac output was measured in triplicate from the same catheter by the thermodilution technique. Each thermodilution curve was recorded and inspected for technical accuracy while the cardiac output was calculated by a thermodilution computer. Arterial pressure was measured from a short, indwelling radial artery catheter. Mean pressures were obtained by electronic damping. The calculations for the hemodynamic variables, systemic vascular resistance, stroke volume index and stroke work index were performed using standard formulas.
Arterial and mixed venous blood samples were measured for Po2, Pco2 and pH (Corning Gas Analyzer, Medfield, Massachusetts day for each of the two exercises. Exercise was performed supine in progressive work load stages on a table-mounted leg ergometer. The initial work load was 50 kpm/min and the work load was increased by 50 kpm in 3-minute stages. Patients maintained a constant pedaling rate of 40 rpm. Measurements were taken at maximum symptom-limited exercise, defined by the patients as intolerable symptoms of generalized fatigue, leg fatigue and dyspnea. Patients were only included in this study if they achieved the same peak exercise while on vasodilator drug as at control and if total pedaling duration was within 30 seconds on vasodilator drug as at control. One patient initially entered into this study was excluded from data analysis because the two exercises were not equal. In this group of patients, peak exercise work load varied from 100 kpm/min to 300 kpm/min, while total pedaling duration varied from 6-18 minutes.
Drug Protocol
After control exercise, vasodilator therapy was begun. Five patients received hydralazine only and four received prazosin only. Four patients received both drugs in sequence: Two received hydralazine first and two received prazosin first. The washout period between the two drugs was a median of 36 hours (range 24-48 hours). The drugs were administered every 6 hours for 36-48 hours in incremental doses to a plateau, based on our experience of doses expected to increase exercise cardiac output.1 2 The plateau dose for hydralazine was 75 mg every 6 hours in each patient; for prazosin it varied between 5-10 mg every 6 hours between patients. Patients were reexercised 2 hours after the final dose of vasodilator.
Statistical Analysis
Paired analysis between control and vasodilator for each variable was performed by the paired t test.
Results Cardiac Output ( fig. 2) In the hydralazine group, cardiac output during control exercise was 5.8 ± 2.3 1/min (mean ± SD). During hydralazine exercise increased to 6.9 i 2.3 1/min (p < 0.001). In the prazosin group, cardiac output during control exercise was 5.9 ± 2.3 1/min. During prazosin exercise increased to 7.6 ± 2.7 1/min (p < 0.005). Cardiac output increased during vasodilator exercise compared with control exercise because stroke volume increased, while heart rate remained unchanged. Combining both vasodilatortreated groups, cardiac output increased during exercise compared with control.
Oxygen Consumption ( fig. 3) In the hydralazine group, oxygen consumption during control exercise was 663 ± 249 ml/min and during hydralazine exercise was 651 ± 200 ml/min (p > 0.10). Four patients showed an increase in oxygen consumption, four showed a decrease, and one showed no change. In the prazosin group, oxygen con- In the hydralazine group, peak lactate during control recovery was 49.7 ± 24.2 mg/dl; during hydralazine recovery it was 44.0 ± 21.4 mg/dl (0.10 > p > 0.05). Seven patients showed a decrease in lactate and two patients showed an increase. In the prazosin group, peak lactate during control recovery was 33.8 ± 16.5 mg/dl and during prazosin recovery was 32.1 ± 12.2 mg/dl (p > 0.10). Four patients showed a decrease in lactate and four an increase. Combining both vasodilator-treated groups, peak lactate did not change compared with control. [8] [9] [10] [11] Therefore, a key question as to the usefulness of vasodilator treatment of chronic heart failure is how cardiovascular transport changes. Transport should be considered in terms of tissue blood flow and of tissue uptake, utilization and removal of metabolites. Some data are available on tissue blood flow in chronic heart failure patients. At rest, there is less-than-normal blood flow to many tissues.12 During exercise, there is less-thannormal blood flow to exercising limbs, and it is likely that this decrease applies specifically to the skeletal muscle of the limb.13 14 Some data are also available on oxygen consumption and lactate in chronic heart failure patients. At rest there is a normal oxygen consumption and normal blood lactate.`During exercise there is a less-than-normal oxygen consumption and a higher-than-normal blood lactate.15 Our data, collected without normal patient controls, show that chronic heart failure patients have a high blood lactate at low work loads. These data suggest that heart failure patients have not only a decreased maximum oxygen consumption but also an accumulating anaerobic debt at submaximum work loads.
Short-term vasodilators increased cardiac output during exercise, but did not change oxygen consumption or blood lactate. Similar findings have been reported in several studies in which cardioactive drugs were administered to heart failure patients on a shortterm basis. For example, phentolamine increased cardiac output but did not change oxygen consumption during bicycle" or forearm exercise.14 Also, prazosin increased cardiac output but did not change oxygen consumption during bicycle exercise.1 Similar results have been reported with nitroglycerin ointment,10 a combination of nitrate-hydralazine,16 and the inotropic agent salbutamol.17 In a group of valvular heart disease patients, nitroglycerin slightly increased exercise oxygen consumption.9 Our data help to explain why short-term drug studies of chronic heart failure may show an increase in exercise cardiac output without an increase in exercise tolerance; but they do not reveal why an acute increase in the cardiac output of heart failure patients does not change oxygen consumption or lactate metabolism. We speculate that there are two classes of physiologic mechanisms to account for this disparity.
First, there may be maldistribution of the increase in cardiac output caused by short-term vasodilators. If this increase were distributed to nonexercising tissues, then exercising skeletal muscle would not benefit from the increase in total flow. Only limited regional measurements of flow in heart failure patients during exercise have been made. It is often believed that metabolic needs are the principal control of organ blood flow during exercise. Vasodilators such as a blockers or direct smooth-muscle agents may not affect the metabolically determined blood flow in exercising skeletal muscle, but instead, blood flow in-CI RCULATION 546 A recent report on the effects of chronic nitrate administration suggests that oxygen consumption and exercise tolerance improved without a change in cardiac output.24
In summary, our study shows that short-term administration of vasodilators does not improve the abnormal peripheral metabolic processes of heart failure patients during exercise or during recovery from exercise. This study also raises exciting possibilities for the study of abnormal cardiovascular transport functions in heart failure.
